Lillie D. Shockney RN, BS, MAS, HON-ONN-CG
University Distinguished Service Professor of Breast Cancer, Professor of Surgery, Johns Hopkins University School of Medicine; Co-Founder, Academy of Oncology Nurse & Patient Navigators; Co-Developer, Work Stride — Managing Cancer at Work, Johns Hopkins Healthcare Solutions, Baltimore, MarylandProf. Lillie D. Shockney, a specialist in the care of patients with breast cancer, is well-known in the cancer field, especially the areas of navigation, survivorship, patient-centered care, preservation of quality of life, end-of-life planning and care, improving the cancer patient’s experience, and clinical outcomes. Her research focuses on the preservation of quality of life for patients with metastatic breast cancer.
In 2016, Prof. Shockney was promoted to full professor, and she is the only nurse at Johns Hopkins to have a primary faculty appointment in the School of Medicine and the only nurse in the country to have reached the highest academic faculty ranking and be appointed to a faculty chair as a University Distinguished Service Professor of Breast Cancer at Johns Hopkins University School of Medicine.
Prof. Shockney is the co-founder of the Academy of Oncology Nurse & Patient Navigators (AONN+), a national professional organization for those working in the navigation space with oncology patients, which has more than 9000 members. She has served as a consultant for breast cancer for ABC News and Good Morning America and has been consulted regularly by the Today Show and CNN. She currently serves on 28 medical advisory boards. She has authored 30 books and more than 350 articles on breast cancer and on topics such as oncology navigation, survivorship, and patient advocacy. She has received 62 awards — 54 national awards, 7 state awards, and 1 international award, and several national lifetime achievement awards.
Disclosures
- Speakers bureau for Pfizer Oncology
Recent Contributions to PracticeUpdate:
- Provider and Patient Perspectives Regarding Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer
- Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in Patients With ER+/HER2− Metastatic Breast Cancer
- Discordance in PIK3CA Mutational Status Between Primary and Metastatic Breast Cancer
- Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
- Expert Consensus Statements on the Definition, Diagnosis, and Management of HER2-Low Breast Cancer
- Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients With Previously Treated HR+/HER2+ Breast Cancer
- Pembrolizumab Plus Paclitaxel or Capecitabine as First- or Second-Line Therapy for Metastatic TNBC
- Alternating 17β-Estradiol and Aromatase Inhibitor Therapies in Postmenopausal Women With Advanced Endocrine-Resistant ER+ Breast Cancer
- Real-World Treatment Patterns and Outcomes Associated With Sequential and Non-Sequential Use of CDK4/6 Inhibitors in Patients With HR+ HER2− MBC
- Plasma cfDNA PIK3CA and TP53 Mutations Predicted Inferior Endocrine-Based Treatment Outcomes in Patients With ER+ Metastatic Breast Cancer